Mucormycosis Research
Thanks to our donors’ generosity, the Henry Schueler 41 & 9 Foundation advances groundbreaking research on mucormycosis, a rare but life-threatening fungal infection that affects children and cancer patients with compromised immune systems. By partnering with leading researchers and institutions, we are helping drive new treatments and education worldwide.
We are proud to be affiliated with Dr. Thomas J. Walsh, MD, PhD, FIDSA, FAAM,FECMM, Henry Schueler Foundation Scholar, Founding Director, Center for Innovative Therapeutics and Diagnostics, Adjunct Professor of Medicine, Microbiology & Immunology, University of Maryland School of Medicine Adjunct Professor of Pathology, John’s Hopkins University School of Medicine one of the world’s leading research physicians in fungal disease.
Training & Education Worldwide
”
“Stay Strong – We’re going to beat this thing.“
“Training and education of health care workers in mucormycosis is a key component of my mission as the Henry Schueler Foundation Scholar.”
– Dr. Thomas Walsh
Breakthrough in Treatment
Through our donors’ support, the Foundation contributed to the development of Cresemba, a groundbreaking antifungal drug now used to treat mucormycosis worldwide. This breakthrough offers hope and life-saving options for patients with weakened immune systems facing this rare but deadly infection.
Research Milestones
First International Conference
2010
- Sponsored the first international conference in Chicago on Mucormycosis.
- Brought together leading global experts for the first time.
- Led to collaboration and a landmark publication in Clinical Infectious Disease.
Comprehensive Medical Supplement Published
2012
- Foundation funded the world’s most comprehensive supplement on Zygomycosis (mucormycosis), published by Oxford University Press.
- Distributed to nearly 12,000 global medical professionals.
- Edited by Dr. Thomas Walsh, it remains the most authoritative research body on mucormycosis.
NORD Rare Impact Award
2016
- Foundation presented a Rare Impact Award to Astellas for developing Cresemba, a breakthrough antifungal drug.
- Today, Cresemba is effectively used worldwide to treat mucormycosis, saving lives and improving outcomes.
Continuing Henry’s Legacy Through Research, Awareness, and Patient Support
Our mission, led by Dr. Walsh, is to develop new strategies for diagnosis, treatment, and prevention of invasive mucormycosis; raise public awareness of its risks; and provide outreach to patients, families, and physicians worldwide.
